Antibe Therapeutics (CVE:ATE)

Antibe Therapeutics (CVE:ATE)

Share Price
$ 0.32
0.005 (1.61 %)
Market Cap
$76.58 m
Proactive Investors - Run By Investors For Investors

Antibe Therapeutics

Antibe Therapeutics is a publicly-traded biotechnology company pursuing a breakthrough advance in the treatment and prevention of inflammation. Antibe's drug pipeline addresses a $20+ billion market in non-addictive pain management, cardiovascular disease, and cancer prevention. Antibe’s lead drug, now in late Phase 2 trials, is demonstrating unprecedented safety and efficacy in the...

Market: TSX-V:ATE
52-week High/Low: C$0.39 / C$0.24
Sector: Pharma & Biotech
Market Cap: $76.58 m
col 3
col 4
col 5
col 6

Big Picture – A Deep Dive Examination of Antibe Therapeutics

Antibe Therapeutics Timeline

Copyright ©, 2019. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use